Amlodipine Besylate/Rosuvastatin Calcium

苯磺酸氨氯地平/瑞舒伐他汀钙

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAmlodipine Besylate/Rosuvastatin Calcium
Drug Alias Name瑞舒伐他汀钙/苯磺酸氨氯地平Rosuvastatin Calcium/Amlodipine BesylateAmlodipine/Rosuvastatinosuvastatin/amlodipineRosuampin +[6] 
ClassificationSmall molecules
Mechanisms of ActionVoltage-gated calcium channel blockersHMG-CoA reductase inhibitors
TargetsVoltage-gated calcium channelHMG-CoA reductase
Therapy Area/IndicationsHypercholesterolemiaHyperlipidemiasHypertension
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth Korea
CombinationsYes Amlodipine BesylateRosuvastatin Calcium
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAlvogen Korea
Active IndicationsN/A
Inactive IndicationsHypercholesterolemiaHyperlipidemiasHypertension

Other Information

ATC CodeN/A
Related LinksN/A